Beryl Drugs quarterly results and financials

Beryl Drugs (BSE 524606)₹25.49−1.47%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Mar 2026 quarter (standalone), Beryl Drugs reported sales of ₹5.48 Cr, up 4.8% from Mar 2025, and net profit of ₹0.55 Cr, up 292.9% year on year. For the year to Mar 2026, sales were ₹19.34 Cr and net profit ₹0.41 Cr.

Sales (Mar 2026): ₹5.48 Cr
Net profit (Mar 2026): ₹0.55 Cr
Sales (FY Mar 2026): ₹19.34 Cr
Net profit (FY Mar 2026): ₹0.41 Cr
EPS (Mar 2026): ₹1.09
Borrowings (Mar 2026): ₹2.45 Cr

Company filings, standalone accounts; latest reported quarter Mar 2026

Beryl Drugs quarterly results

₹ crore unless stated; each column is a quarter.

Beryl Drugs Quarterly results
	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	8.19	8.10	7.67	3.22	6.30	5.65	5.41	5.23	4.84	5.17	3.86	5.48
Expenses	7.06	7.39	6.88	3.20	5.31	5.09	4.82	4.73	4.29	4.44	4.06	4.14
Operating Profit	1.12	0.71	0.78	0.01	0.98	0.55	0.58	0.49	0.54	0.72	−0.19	1.33
OPM %	13.8%	8.8%	10.2%	0.6%	15.7%	9.9%	10.9%	9.5%	11.4%	14.1%	−5.2%	24.4%
Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest	0.11	0.09	0.10	0.12	0.20	0.11	0.11	0.07	0.09	0.07	0.08	0.06
Depreciation	0.29	0.30	0.32	0.33	0.29	0.34	0.32	0.33	0.39	0.40	0.33	0.41
Profit before tax	0.74	0.34	0.38	−0.44	0.51	0.12	0.17	0.11	0.08	0.27	−0.62	0.88
Tax %	27.3%	18.1%	16.1%	−16.3%	25.9%	90.8%	62.4%	−50.1%	71.4%	96.1%	−72.2%	34.4%
Net Profit	0.52	0.26	0.30	−0.34	0.36	0.00	0.04	0.14	0.01	0.00	−0.16	0.55
EPS (Rs)	1.04	0.52	0.62	−0.68	0.72	0.03	0.09	0.29	0.05	0.01	−0.33	1.09

Beryl Drugs profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Beryl Drugs Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	13.01	10.91	15.09	12.83	12.79	14.05	14.50	26.88	26.77	21.16	19.34	19.35
Expenses	12.51	10.98	14.06	11.80	11.90	12.61	14.06	24.86	24.50	19.94	16.92	16.93
Operating Profit	0.49	−0.05	1.03	1.02	0.90	1.44	0.43	1.99	2.27	1.23	2.41	2.40
OPM %	3.8%	−0.6%	6.9%	8.0%	7.1%	10.3%	3.0%	7.4%	8.5%	5.8%	12.5%	12.4%
Other Income	0.36	0.26	0.68	0.23	0.22	0.63	0.15	0.26	0.39	1.40	0.00	0.00
Interest	0.20	0.19	0.12	0.14	0.31	0.46	0.45	0.46	0.46	0.53	0.33	0.30
Depreciation	0.42	0.39	0.34	0.33	0.67	1.28	1.10	0.82	1.21	1.26	1.50	1.53
Profit before tax	0.26	−0.38	1.28	0.81	0.17	0.36	−0.96	1.00	1.02	0.87	0.60	0.61
Tax %	31.9%	18.8%	22.0%	26.2%	68.7%	31.4%	−30.6%	22.2%	23.7%	33.6%	27.1%	—
Exceptional items	0.00	0.00	0.35	0.00	0.00	0.33	0.00	0.00	0.00	0.00	0.00	—
Net Profit	0.16	−0.44	0.98	0.58	0.04	0.23	−0.65	0.76	0.76	0.57	0.41	0.40
EPS (Rs)	0.35	−0.88	1.94	1.17	0.09	0.48	−1.29	1.51	1.51	1.13	0.82	0.82
Dividend payout %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—

Beryl Drugs balance sheet

₹ crore, at each year end.

Beryl Drugs Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	5.10	5.09	5.08	5.10	5.08	5.08	5.08	5.08	5.08	5.10	5.10	5.08
Reserves	1.39	1.56	0.78	1.56	2.42	2.52	2.83	2.19	2.96	3.82	4.40	4.78
Borrowings	1.73	1.68	1.73	1.49	3.26	5.24	5.13	5.30	4.55	5.08	4.06	2.45
Other Liabilities	2.70	1.81	2.85	2.68	3.81	4.08	5.60	5.25	4.92	3.50	2.40	2.65
Total Liabilities	10.92	10.14	10.44	10.83	14.57	16.92	18.64	17.82	17.51	17.50	15.96	14.96
Fixed Assets	2.44	2.45	2.26	2.23	1.97	8.62	7.53	6.05	6.04	6.19	6.21	7.05
CWIP	0.25	0.00	0.00	0.09	6.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.67	0.67	0.48	0.21	0.47	0.55	0.11	0.15	0.14	0.00	0.00	0.00
Other Assets	7.56	7.02	7.70	8.30	5.88	7.75	11.00	11.62	11.33	11.31	9.75	7.91
Inventories	1.49	1.53	2.68	1.34	0.75	1.15	2.26	2.97	1.04	1.25	1.89	3.12
Trade receivables	3.68	3.56	3.05	4.81	3.43	3.44	4.52	4.44	6.87	7.56	5.44	2.08
Cash & equivalents	0.81	0.62	0.64	0.13	0.09	0.39	0.44	0.26	0.58	0.11	0.80	0.28
Total Assets	10.92	10.14	10.44	10.83	14.57	16.92	18.64	17.82	17.51	17.50	15.96	14.96

Beryl Drugs cash flow

₹ crore, for each year.

Beryl Drugs Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	0.69	−0.12	0.36	−0.09	3.34	0.17	0.33	−0.28	2.47	0.81	2.63	3.64
Cash from investing activity	0.01	0.16	0.31	−0.02	−5.00	−1.54	0.25	0.53	−1.29	−1.07	−0.39	−2.15
Cash from financing activity	−0.10	−0.22	−0.20	−0.35	1.61	1.68	−0.55	−0.42	−1.16	0.11	−1.54	−2.02
Net cash flow	0.62	−0.18	0.49	−0.48	−0.05	0.29	0.07	−0.17	0.00	−0.15	0.70	−0.55
Capex	0.27	0.19	0.19	0.29	0.08	1.87	1.04	0.41	1.55	1.34	2.18	3.81
Free cash flow	0.48	−0.34	0.20	−0.02	−2.88	−1.71	0.11	0.11	1.74	−0.52	1.36	−0.18
CFO / OP %	125.0%	6.0%	−833.1%	1.0%	349.9%	35.9%	24.9%	−43.1%	126.9%	44.9%	226.9%	156.9%

Beryl Drugs ratios

Working-capital days and returns, by year.

Beryl Drugs Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	103	102	103	118	99	100	119	113	95	105	95	41
Inventory days	64	65	151	53	40	487	1,135	—	246	—	—	117
Days payable	71	35	66	58	95	756	1,111	—	759	—	—	54
Cash conversion cycle	96	131	188	112	43	−171	142	111	−420	103	93	102
Working capital days	38	58	67	72	−7	14	39	47	47	58	68	39
ROCE %	5.2%	5.6%	−2.3%	12.0%	10.0%	4.1%	2.9%	−3.8%	11.7%	11.1%	10.2%	7.2%

Beryl Drugs: frequently asked questions

What are the latest quarterly results of Beryl Drugs?

For the Mar 2026 quarter, Beryl Drugs reported sales of ₹5.48 Cr, up 4.8% year on year and net profit of ₹0.55 Cr, up 292.9% year on year. The operating margin was 24.4%.

What is the annual revenue of Beryl Drugs?

Beryl Drugs' sales for the year to Mar 2026 were ₹19.34 Cr; over the last twelve months they were ₹19.35 Cr.

What is the net profit of Beryl Drugs?

Net profit for the year to Mar 2026 was ₹0.41 Cr, and ₹0.40 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.82.

How much debt does Beryl Drugs have?

Beryl Drugs reported borrowings of ₹2.45 Cr at Mar 2026, against cash and equivalents of ₹0.28 Cr.

What is the free cash flow of Beryl Drugs?

Cash from operations was ₹3.64 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹0.18 Cr.

Loading…